A5067045410- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- DNA Repair Mechanisms
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Angiogenesis and VEGF in Cancer
- Advanced Breast Cancer Therapies
- Virus-based gene therapy research
- Genetic factors in colorectal cancer
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Bone health and treatments
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Nanoparticle-Based Drug Delivery
- Oral and Maxillofacial Pathology
University Hospital of Basel
2015-2025
University of Basel
2006-2023
Swiss Group For Clinical Cancer Research
2003-2023
Breast Center
2015
Stiftung Tumorforschung Kopf-Hals
2013
McMaster University
2011-2012
University of California, Los Angeles
2012
Hospital Base
2007-2010
University Hospital of Bern
2007-2009
Kantonsspital Aarau
2009
The ability of circulating tumor cells (CTCs) to form clusters has been linked increased metastatic potential. Yet biological features and vulnerabilities CTC remain largely unknown. Here, we profile the DNA methylation landscape single CTCs from breast cancer patients mouse models on a genome-wide scale. We find that binding sites for stemness- proliferation-associated transcription factors are specifically hypomethylated in clusters, including OCT4, NANOG, SOX2, SIN3A, paralleling...
To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers.In a clinical phase II single-center open-label trial, patients with cancers were treated repeated cycles [(90)Y-DOTA]-TOC. Each cycle consisted single intravenous injection 3.7GBq/m(2) body-surface Additional withheld case tumor progression and/or permanent...
Abstract Background Insulin-like growth factor-1 (IGF-I) signalling is important for cancer initiation and progression. Given the emerging evidence role of stroma in these processes, we aimed to characterize effects IGF-I on cells stromal separately. Methods We used an ex vivo culture model measured gene expression changes after stimulation with cDNA microarrays. In vitro data were correlated findings by comparing results published datasets human biopsies. Results Upon IGF-I, breast...
Circulating tumor cells (CTCs) are shed from solid cancers in the form of single or clustered cells, and latter display an extraordinary ability to initiate metastasis. Yet, biological phenomena that trigger shedding CTC clusters a primary cancerous lesion poorly understood. Here, when dynamically labeling breast cancer along progression, we observe majority undergoing hypoxia, while CTCs largely normoxic. Strikingly, find vascular endothelial growth factor (VEGF) targeting leads shrinkage,...
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily...
PURPOSE: To study the additional benefit from adenoviral p53 gene therapy in patients undergoing first-line chemotherapy for advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Twenty-five with nonresectable NSCLC were enrolled an open-label, multicenter phase II of three cycles regimen A, carboplatin (area under curve, 6; day 1) plus paclitaxel (175 mg/m 2 , 1), or B, cisplatin (100 vinorelbine (25 days 1, 8, 15, and 22) combination intratumoral injection 7.5 × 10 12...
Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide versus combination radioisotopes.In cohort study, patients metastasized neuroendocrine cancer were treated repeated cycles (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) or alternating between [(90)Y-DOTA]-TOC and (177)lutetium-labeled DOTA-TOC ([(177)Lu-DOTA]-TOC) until tumor progression...
We aimed to explore the efficacy of (90)Yttrium-1,4,7,10-tetra-azacyclododecane N,N',N'',N-'''-tetraacetic acid ((90)Y-DOTA)-Tyr(3)-octreotide (TOC) therapy in advanced medullary thyroid cancer.In a phase II trial, we investigated response, survival, and long-term safety profile systemic [(90)Y-DOTA]-TOC treatment metastasized cancer. Adverse events were assessed according criteria National Cancer Institute. Survival analyses done using multiple regression models.Thirty-one patients...
Purpose Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis. We analyzed long-term follow-up (LTFU) of efficacy outcomes and adverse events in the Breast International Group (BIG) 1-98 study reported median 12.6 years. Patients Methods BIG is four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) their sequences (2 one plus 3 other) postmenopausal women...
Abstract Background The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many types tissues. expressed, but heavily underglycosylated, different human tumors. TG4010 viral suspension recombinant vaccinia vector (MVA) containing DNA sequences coding for antigen and interleukin‐2 (IL‐2). This product was developed use as vaccine cancer patients whose tumors express antigen. objective present study to determine safety define...
Mutations of the tumor suppressor gene p53 are most common genetic alterations observed in human cancer. Loss wild-type function impairs cell cycle arrest as well repair mechanisms involved response to DNA damage. Further, apoptotic pathways induced by radio- or chemotherapy also abrogated. Gene transfer was shown reverse these deficiencies and induce apoptosis vitro preclinical vivo models. A phase I dose escalation study a single intratumoral injection replication-defective adenoviral...
CEACAM6, CEACAM1, and human carcinoembryonic antigen (CEA) are coexpressed in normal colorectal epithelia, but show deregulated expression cancers (CRC). Upregulation of CEACAM6 hyperplastic polyps early adenomas represents one the earliest observable molecular events leading to tumors. The aim our study was evaluate prognostic relevance CEA tissue patients with CRC.Immunohistochemical analysis carried out on microarrays from 243 paraffin-embedded biopsies a randomized controlled clinical...
Angiogenesis is a key process in tumor progression. By binding VEGF, VEGF receptor-2 (VEGFR2) main signaling transducer tumor-associated angiogenesis. Accordingly, therapeutic approaches against the VEGF/VEGFR2 axis have been designed. However, an efficient and specific chemotherapeutic targeting of endothelial cells has not yet achieved.We employed anti-VEGFR2 antibodies covalently linked to pegylated liposomal doxorubicin (PLD) specifically ablate Rip1Tag2 mouse model insulinoma, MMTV-PyMT...
Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis poor and more than three quarters of patients experience progression 12 months after the initiation conventional first-line chemotherapy. Approximately two thirds TNBC express epidermal growth factor receptor 1 (EGFR). We have developed anti-EGFR targeted nanocontainer drug by inserting antibody fragments into membrane pegylated liposomes (anti-EGFR-ILs-dox). payload consists...